Search results

Selected filters:

Valuation
Europe

Article type

Topic

Sector

Jurisdictions

69 results found for your search

Sort options
26 August 2019

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

19 July 2019

Alphabet is trimming down its portfolio - but only after sustained growth  

The tech giant saw a steep drop in the number of US patents granted in 2018 after having spent years building its portfolio organically and through strategic acquisitions

16 July 2019

Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline

05 July 2019

Get ready for the first CRISPR patent pool

In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’

02 July 2019

AbbVie’s Allergan play designed to mitigate Humira patent cliff

The $63 billion purchase is designed to mitigate the effects of losing the exclusive rights to the world’s best selling drug

13 June 2019

Huawei’s $1 billion Verizon demand: politics or profit?

Ongoing royalty negotiations are revealed after US network operator reportedly notifies government. Why the conflict, which follows a 2016 dispute with T-Mobile, may alarm Nokia and Ericsson

12 June 2019

IAM and sister publication GDR launch major data event

The Data Business Congress will take place in San Jose, CA, next February with the focus on the capture, protection, management, exploitation and monetisation of one of the pivotal assets of the 21st century

07 June 2019

Roche trumps rivals with strongest biotech patent portfolio

Trailing behind the Swiss giant are DowDuPont and Bayer, both of which have seen a drop in the value of their holdings

03 June 2019

Deloitte makes major IP play with acquisition of top advisory

Big Four firm closes deal to acquire UK-based ClearView in a further sign that IP value creation is moving to the centre of the corporate agenda 

05 April 2019

Analysis of Fujifilm’s portfolio shows R&D strategy has opened doors to high-growth industries

The Japanese photography and imaging company has focused on developing peripheral technologies to expand into the medical and pharmaceuticals sectors; but while its holdings have increased in quality over the years, it still has a way to go

06 March 2019

The state of play in the global IP market

IAM's annual benchmarking survey is designed to identify the key concerns of senior decision makers in areas such as deal-making, valuation, patent office performance, top litigation venues and policy 

23 January 2019

Welcome to the future of patents

New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond

04 January 2019

In licensing battle with Qualcomm, Apple is now in a very unfamiliar position

When it fought the smartphone wars, the iPhone giant was riding the crest of a sales wave; the current dispute, though, is being conducted as times get tougher

30 November 2018

How a Chinese court would have decided the <em>Unwired Planet</em> appeal

Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions 

30 November 2018

Time is running out to nominate the world’s leading IP strategists

There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.